Global Enteric Empty Capsules Market Growing at CAGR of 8.3% By 2031
Category : Pharmaceuticals And Healthcare | Published Date : Jul 2024
Enteric Empty Capsules Market Scope & Overview :
An enteric empty capsule is designed to resist disintegration in the stomach, allowing its contents to be effectively absorbed in the small intestine. It simplifies drug delivery, protects the stomach, and offers better-targeted delivery of nutrients. These capsules have a longer shelf life than traditional empty capsules.
Consegic Business Intelligence analyzes that the Global Enteric Empty Capsules Market size was valued at USD 73.31 Million in 2022, is predicted to reach over 78.47 Million in 2023, and is expected to register a CAGR of 8.3% to reach USD 148.23 Million by 2031.
This report comprises Enteric Empty Capsules Market Share, Size & Industry Analysis, By Type (Gelatin and Non-Gelatin), By Therapeutic Application (Antibiotic and Antibacterial Drugs, Antacid and Antiflatulent Preparations, Dietary Supplements, Cardiovascular Therapy Drugs, and Others), By End-user (Pharmaceutical and Biopharmaceutical Companies, Cosmetic Companies, Nutraceutical Companies, Clinical Research Organizations, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa), and Forecast, 2023-2031.
This report contains detailed information on Enteric Empty Capsules Market Opportunities, Trends, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraint or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
As per the report analysis, the demand for enteric empty capsules is increasing due to their essential role in providing supplements and medications for treating chronic diseases. They offer accurate dosage and are crucial in treating conditions such as cancer, heart disease, diabetes, and respiratory illness. Innovations in capsule manufacturing technology and new products are boosting market opportunities.
Segmental Analysis :
The Enteric Empty Capsules Market is segmented based on type, therapeutic application, end-user, and region.
Based on the type, the market is bifurcated into Gelatin and Non-Gelatin.
- In 2022, gelatin capsules dominate with the highest revenue and are predicted to grow at the fastest rate over the forecasted period due to low cost, high availability, and health benefits. They are widely used in pharmaceuticals and nutraceuticals for joint and skin disorders.
Based on the therapeutic application, the market is segregated into Antibiotic and Antibacterial Drugs, Antacid and Antiflatulent Preparations, Dietary Supplements, Cardiovascular Therapy Drugs, and Others.
- The dietary supplements segment held the highest market share in 2022 and is expected to grow at the fastest rate in enteric empty capsules during the forecasted period, due to increasing demand driven by wide availability, health consciousness, and a growing focus on personalized nutrition.
Based on the end-user, the market is segmented into Pharmaceutical and Biopharmaceutical Companies, Cosmetic Companies, Nutraceutical Companies, Clinical Research Organizations, and Others.
- In 2022, the nutraceutical companies segment held the highest market share of 32.79% in the enteric empty capsules market. Increased nutraceutical intake for boosting immunity and a growing focus on healthy lifestyles are driving the segment's demand.
- The cosmetic companies segment is expected to experience the fastest growth over the forecasted period, driven by the use of enteric empty capsules in treating skin problems and enhancing beauty.
By region, the market is segregated into regions including North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
- In 2022, North America accounted for the highest market share at 33.56%, valued at USD 24.60 million in 2022 and USD 26.16 million in 2023, expected to reach USD 48.31 million in 2031. The U.S. held the highest market share of 86.23% in 2022 due to key players, advanced healthcare facilities, and government initiatives.
- The Asia Pacific is expected to grow significantly at a CAGR of 8.9% during 2023-2031 due to the expanding pharmaceutical and nutraceutical industries.
| Report Attributes | Report Details |
| By Type | Gelatin and Non-Gelatin |
| By Therapeutic Application | Antibiotic and Antibacterial Drugs, Antacid and Antiflatulent Preparations, Dietary Supplements, Cardiovascular Therapy Drugs, and Others |
| By End-User | Pharmaceutical and Biopharmaceutical Companies, Cosmetic Companies, Nutraceutical Companies, Clinical Research Organizations, and Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Enteric Empty Capsules Industry :
- Lonza Group Ltd
- Evonik
- The Roxlor Group
- CapsCanada Corporation
- Qualicaps Inc.
- CapsulCN International Co., Ltd.
- Natural Capsules Limited
- Snail Pharma Industry Co. Ltd
- ACG Group
- Anhui Huangshan Capsule Co., Ltd.
Recent Industry Developments :
- In May 2021, Evonik launched the EUDRACAP platform to help the pharmaceutical industry speed up the development of complex oral drug products.
- In November 2022, Lonza Group Ltd introduced the Enprotect capsule for intestinal drug delivery, which doesn't disintegrate in the stomach.